Inferra AI / Company / JAZZ
Jazz Pharmaceuticals Plc
JAZZ · Health Care
Last earnings Aug 3, 2026
Key results
Xywav revenuequarter
13%
Xywav revenues grew 13% YoY with 525 net patient adds in 2Q26
SEC original ↗Jazz Pharmaceuticals Plc — Earnings release (8-K exhibit)EX-99Aug 3, 2026
Epidiolex revenuequarter
16%
Epidiolex revenues grew 16%
SEC original ↗Jazz Pharmaceuticals Plc — Earnings release (8-K exhibit)EX-99Aug 3, 2026
Revenuequarter
$1.2 billion
Recent Key Highlights Highest ever total quarterly revenues of $1.2 billion with 16% year-over-year (YoY) growth.
SEC original ↗Jazz Pharmaceuticals Plc — Earnings release (8-K exhibit)EX-99Aug 3, 2026
Total revenuequarter
16%
Total revenues increased 16% in 2Q26 YoY primarily due to higher Xywav, Epidiolex Epidyolex and Zepzelca net product sales and the inclusion of Modeyso net product sales, following FDA approval in August 2025.
SEC original ↗Jazz Pharmaceuticals Plc — Earnings release (8-K exhibit)EX-99Aug 3, 2026
AI analysis
Q2 2026 · reported Aug 3, 2026
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Headline figures
| Metric | Q2 2026 | Prior qtr | Year ago |
|---|---|---|---|
| Xywav revenue | 13% | — | — |
| Epidiolex revenue | 16% | — | — |
| Revenue | $1.2 billion | — | — |
| Total revenue | 16% | — | — |
Guidance · company-stated
Direction: Raised
“2 billion (+16% YoY) Company raises 2026 revenue guidance Prepared to launch Ziihera in HER2+ 1L GEA immediately following FDA approval Xywav revenues grew 13% YoY with 525 net patient adds in 2Q26 Epidiolex revenues grew 16% YoY DUBLIN, August 3, 2026 -- Jazz Pharmaceuticals plc (Nasdaq JAZZ) today announced financial results for the second quarter of 2026 (2Q26) and raised revenue guidance for 2026.”
“Our second quarter results highlight strong execution and momentum across the business, delivering 16% year-over-year total revenue growth and driving a considerable increase to our full-year revenue guidance, said Renee Gala, president and chief executive officer of Jazz Pharmaceuticals.”
“Following strong 1H26 commercial execution, the company raised its 2026 revenue guidance range to $4.”
Classified from the release's primary full-year outlook statement.
Capital allocation
4 Cash Flow and Balance Sheet As of June 30, 2026, cash, cash equivalents and investments were $2.2 billion, and the outstanding principal balance of the company s long-term debt was $4.4 billion.
In addition, the company had undrawn borrowing capacity under a revolving credit facility of $885 million.
Event summary
Generated GAAP non-GAAP 1 adjusted earnings per share (EPS) of $2.78 $5.71 with $824 million in cash from operations in the first half of 2026
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance & outlook
Direction: Raised
Revenue: “2 billion (+16% YoY) Company raises 2026 revenue guidance Prepared to launch Ziihera in HER2+ 1L GEA immediately following FDA approval Xywav revenues grew 13% YoY with 525 net patient adds in 2Q26 Epidiolex revenues grew 16% YoY DUBLIN, August 3, 2026 -- Jazz Pharmaceuticals plc (Nasdaq JAZZ) today announced financial results for the second quarter of 2026 (2Q26) and raised revenue guidance for 2026.”
Revenue: “Our second quarter results highlight strong execution and momentum across the business, delivering 16% year-over-year total revenue growth and driving a considerable increase to our full-year revenue guidance, said Renee Gala, president and chief executive officer of Jazz Pharmaceuticals.”
Revenue: “Following strong 1H26 commercial execution, the company raised its 2026 revenue guidance range to $4.”
Revenue — Raised (“raises”)
“2 billion (+16% YoY) Company raises 2026 revenue guidance Prepared to launch Ziihera in HER2+ 1L GEA immediately following FDA approval Xywav revenues grew 13% YoY with 525 net patient adds in 2Q26 Epidiolex revenues grew 16% YoY DUBLIN, August 3, 2026 -- Jazz Pharmaceuticals plc (Nasdaq JAZZ) today announced financial results for the second quarter of 2026 (2Q26) and raised revenue guidance for 2026.”
Revenue — Raised (“increase”)
“Our second quarter results highlight strong execution and momentum across the business, delivering 16% year-over-year total revenue growth and driving a considerable increase to our full-year revenue guidance, said Renee Gala, president and chief executive officer of Jazz Pharmaceuticals.”
Revenue — Raised (“raised”)
“Following strong 1H26 commercial execution, the company raised its 2026 revenue guidance range to $4.”
Classified from the release's primary full-year outlook statement.
Capital allocation
4 Cash Flow and Balance Sheet As of June 30, 2026, cash, cash equivalents and investments were $2.2 billion, and the outstanding principal balance of the company s long-term debt was $4.4 billion.
SEC original ↗Jazz Pharmaceuticals Plc — Earnings release (8-K exhibit)EX-99Aug 3, 2026
In addition, the company had undrawn borrowing capacity under a revolving credit facility of $885 million.
SEC original ↗Jazz Pharmaceuticals Plc — Earnings release (8-K exhibit)EX-99Aug 3, 2026
In June 2026, we repaid the $1.0 billion aggregate principal amount of the 2.00% exchangeable senior notes due 2026.
SEC original ↗Jazz Pharmaceuticals Plc — Earnings release (8-K exhibit)EX-99Aug 3, 2026
Term Description 2026 Notes 2.00% exchangeable senior notes due 2026 2030 Notes 3.125% exchangeable senior notes due 2030 AbCellera AbCellera Biologics Inc.
SEC original ↗Jazz Pharmaceuticals Plc — 10-Q Quarterly report10-QAug 3, 2026
3 Amended Revolving Credit Facility Revolving credit facility amended to increase the Initial Revolving Credit Facility to $885.0 million and extend the maturity date Amendment No.
SEC original ↗Jazz Pharmaceuticals Plc — 10-Q Quarterly report10-QAug 3, 2026
Drug Enforcement Administration Dollar Term Loan our former seven-year $3.1 billion term loan B facility under the Credit Agreement DRD2 dopamine D2 receptor DS Dravet syndrome EC European Commission EDS excessive daytime sleepiness Epidiolex ANDA Filers Teva; Padagis US LLC; Apotex Inc.
SEC original ↗Jazz Pharmaceuticals Plc — 10-Q Quarterly report10-QAug 3, 2026
Strategy & priorities
We remain focused on long-term growth as we prepare to launch Ziihera in HER2+ 1L GEA, advance the zanidatamab and Epidiolex clinical programs, and expand our pipeline through targeted corporate development and internal research and development.
SEC original ↗Jazz Pharmaceuticals Plc — Earnings release (8-K exhibit)EX-99Aug 3, 2026
The combination of commercial execution, portfolio expansion and our strong financial foundation positions Jazz to deliver meaningful innovation for patients and substantial value for shareholders.
SEC original ↗Jazz Pharmaceuticals Plc — Earnings release (8-K exhibit)EX-99Aug 3, 2026
Food and Drug Administration (FDA) granted Priority Review and set Prescription Drug User Fee Act (PDUFA) target action date of August 25, 2026 for supplemental Biologics License Application (sBLA) for zanidatamab containing combinations in first-line (1L) gastroesophageal adenocarcinoma (GEA).
SEC original ↗Jazz Pharmaceuticals Plc — Earnings release (8-K exhibit)EX-99Aug 3, 2026
Pillar Two the OECD framework proposal to implement a two-pillar plan on global tax reform, including a global minimum tax rate of 15% for large multinational corporations on a jurisdiction-by-jurisdiction basis PRC People's Republic of China PRSUs Performance-based restricted stock units PRV priority review voucher Qilu Qilu Pharmaceutical (Hainan) Co.
SEC original ↗Jazz Pharmaceuticals Plc — 10-Q Quarterly report10-QAug 3, 2026
Quarterly Report on Form 10-Q this Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 R&D research and development Redx Redx Pharma plc REMS risk evaluation and mitigation strategy Repricing Amendment No.
SEC original ↗Jazz Pharmaceuticals Plc — 10-Q Quarterly report10-QAug 3, 2026
Risks & headwinds
These forward-looking statements are based on the company s current plans, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties.
SEC original ↗Jazz Pharmaceuticals Plc — Earnings release (8-K exhibit)EX-99Aug 3, 2026
Other risks and uncertainties of which the company is not currently aware may also affect the company's forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated.
SEC original ↗Jazz Pharmaceuticals Plc — Earnings release (8-K exhibit)EX-99Aug 3, 2026
Legal Proceedings 48 Item 1A.
SEC original ↗Jazz Pharmaceuticals Plc — 10-Q Quarterly report10-QAug 3, 2026
No assurances can be given that the covering insurers will not attempt to dispute the validity, applicability, or amount of coverage w ithout expensive litigation against these insurers, in which case we may incur substantial liabilities as a result of these indemnification obligations.
SEC original ↗Jazz Pharmaceuticals Plc — 10-Q Quarterly report10-QAug 3, 2026
Legal Proceedings We are involved in legal proceedings, including the following matters: Patent Infringement Litigation Xywav Patent Litigation In June 2021, we received notice from Lupin, that it has filed with FDA an ANDA for a generic version of Xywav.
SEC original ↗Jazz Pharmaceuticals Plc — 10-Q Quarterly report10-QAug 3, 2026
On May 11, 2022, we filed an additional lawsuit against Lupin in the U.
SEC original ↗Jazz Pharmaceuticals Plc — 10-Q Quarterly report10-QAug 3, 2026
Earnings deck slides
0 decks with slide viewJazz Pharmaceuticals Plc — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
31 documents- Q3 2026
- 8-KJAZZ
Oct 26, 2026
- 8-KJAZZ
- Q2 2026
- 8-KJAZZ
Sep 23, 2026
- 8-KJAZZ
Sep 15, 2026
- 8-KJAZZ
Aug 31, 2026
- 8-KJAZZ
Aug 25, 2026
- 8-KJAZZ
Aug 10, 2026
- 8-KJAZZ
Aug 10, 2026
- 10-QJAZZ
- 8-KJAZZ
- 8-KJAZZ
Jul 24, 2026
- Q1 2026
- 8-KJAZZ
May 29, 2026
- 10-QJAZZ
- 8-KJAZZ
- Q4 2025
- 10-KJAZZ
Feb 24, 2026
- 8-KJAZZ
Feb 24, 2026
- 8-KJAZZ
Jan 12, 2026
- Q3 2025
- 8-KJAZZ
Nov 17, 2025
- 10-QJAZZ
- 8-KJAZZ
- 8-KJAZZ
Oct 28, 2025
- 8-KJAZZ
Oct 22, 2025
- Q2 2025
- 10-QJAZZ
- 8-KJAZZ
- 8-KJAZZ
Jul 25, 2025
- 8-KJAZZ
Jul 10, 2025
- Q1 2025
- 10-QJAZZ
- 8-KJAZZ
- 8-KJAZZ
Apr 21, 2025
- 8-KJAZZ
- Q4 2024
- 8-K/AJAZZ
Earnings releases
10 documentsPresentations
1 document- Q4 2025
- JAZZDeck
Transcripts
0 documentsNo transcripts for Jazz Pharmaceuticals Plc are held in this edition of the library.
Mentioned by
3 companiesOther tracked companies whose held documents mention Jazz Pharmaceuticals Plc by name or ticker. A mention is counted once per document, from the document text the library holds.
“…EX-99.1 2 exhibit991closingpr.htm EX-99.1 Document Exhibit 99.1 Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences Acquisition adds ABS-1230, a clinical-stage, potential first-in-class precision… …governmental e”
“ior Notes due 2032 and Concurrent Ordinary Share Repurchases DUBLIN, August 26, 2026 -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (“Jazz Pharmaceuticals”) today…”
“nior Notes due 2032 and Concurrent Ordinary Share Repurchases DUBLIN, August 27, 2026 — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (“Jazz Pharmaceuticals”) today…”
See also the earnings calendar for every tracked company’s next earnings date.